Orionis Biosciences, a privately held company, announced a second multi-year collaboration with Genentech, a member of the ...

Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new ...

The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

"Integrating the SBX technology into clinical and translational pipelines opens exciting new possibilities,” said Niall ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today plans to invest more than $700 million ...

A new promo for Roche’s blockbuster hemophilia A drug Hemlibra focuses less on those with the genetic bleeding disorder and ...